Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3).
Class II · Ongoing
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Advertisement
Advertisement
Affected lots / codes — check yours against thisLots: a) M411147, Expires: 08/2026; M502100, M502099, Expires: 01/2027.
- Recalling firm
- Zydus Pharmaceuticals (USA) Inc, Pennington, NJ
- Classification
- Class II (temporary or reversible harm possible)
- Status
- Ongoing
- Quantity
- 10,992 bottles
- Distribution
- Nationwide within the U.S
- Recall initiated
- April 29, 2026
- Classified
- May 20, 2026
- Initiation
- Voluntary: Firm initiated
Advertisement
Official source. This record is published by the U.S. FDA through the openFDA
enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0545-2026%22
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0545-2026%22
Advertisement
Important. Recalls target specific lots and codes — compare the affected lots
above against your own product. This page reproduces public FDA data for readability;
EveryRecall is independent and not affiliated with the FDA.
Check this brand across all 8 databases →